The introduction of price controls marks the latest step by Prime Minister Narendra Modi’s government to make drugs and medical devices more affordable. In February, it imposed a 75 percent price cut for certain heart stents – wire mesh tubes used to treat blocked arteries, which caused protests among manufacturers.
India’s drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing.
Ananth Kumar, Minister of Chemicals and Fertilisers, told a news briefing the government had capped knee implant prices “in public interest.”
Kumar said the price of the widely used cobalt chromium knee implant, priced at up to 250,000 rupees ($3,895) at Indian hospitals, would now be capped at 54,720 rupees ($852).
The government will not allow “illegal profiteering, unethical profiteering”, Kumar said.
Major pharmaceutical companies have protested against India’s price controls on drugs and medical devices, arguing this will curb innovation and could hurt future investment plans.
Johnson & Johnson, for example, which makes artificial knees, has been worried about potential price curbs in this area.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022